Premium
Optimizing treatment for HCV genotype 4: PEG‐IFN alfa 2a vs. PEG‐IFN alfa 2b; the debate continues
Author(s) -
Esmat Gamal,
El Kassas Mohamed,
Hassany Mohamed,
Gamil Mohamed,
El Raziky Maissa
Publication year - 2014
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.12397
Subject(s) - ribavirin , genotype , medicine , hepatitis c virus , peg ratio , virology , hepatitis c , pegylated interferon , immunology , virus , biology , gene , genetics , finance , economics
Hepatitis C virus ( HCV ) remains one of the leading causes of morbidity and mortality worldwide. Combined therapy with pegylated interferon ( PEG ‐ IFN ) and ribavirin is the current standard of care treatment for HCV genotype 4. Two types of PEG ‐ IFN are commercially available. The limited number of trials that were conducted for HCV genotype 4 and the few head to head comparisons make it impossible to know which is the best option? In this article we review all available PEG ‐ IFN trials performed worldwide for HCV genotype 4 since 2004. Unless another molecule is developed as a standalone for the treatment of HCV , PEG ‐ IFN will continue to be a source of debate.